AnalytiCon Discovery appoints top-class Scientific Advisory Board

Potsdam, July 2002 - Since the end of June Potsdam based biotech company AnalytiCon Discovery GmbH is aided in its research for tomorrow's medicines by high-level scientific support. The following persons have been appointed to this top-class Scientific Advisory Board:

- Professor Dr. Bernhard Kutscher, Vice President Research and Development at Baxter Oncology, Frankfurt, and Honorary Professor at the Technical University of Munich.
- Professor Dr. Toshikazu Oki, Professor of Applied Microbiology at the Tamagawa University Research Institute, Tokyo, Japan, and former Vice President and Director of Bristol-Myers Squibb
- Professor Dr. Gisbert Schneider, Beilstein-Professor of Cheminformatics at the Johann Wolfgang von Goethe University, Frankfurt, Germany, and former Head of Molecular Design & Bioinformatics at F. Hoffmann-La Roche Ltd., Basel
- Professor Dr. Hugo Kubinyi, Professor of Pharmaceutical Chemistry at the University of Heidelberg, Germany, and former Head of Drug Design at BASF AG, Germany
- Professor Dr. Herbert Waldmann, Professor of Biochemistry at the University of Dortmund, Germany, and Director of the Max-Planck-Institute for Molecular Physiology, Dortmund, Germany

Announcing the appointment of the new advisory board Dr. Lutz Müller-Kuhrt, CEO of AnalytiCon Discovery, remarked: „The vast knowledge and extensive experience concentrated in our Scientific Advisory Board will tremendously boost the development of our company to become a full-service provider of natural compound based drug research. This will extend the expertise of our company to the area of natural compound oriented medical chemistry, and will further strengthen our worldwide leadership in the research on natural compounds.”

AnalytiCon Discovery GmbH
The internationally operating AnalytiCon Discovery GmbH is a worldwide market-leader in the field of structurally fully elucidated natural compound libraries. On the basis of its ready-to-screen technology in the sector of natural compounds (MEGAbolite) and natural compound analogues (NatDiverse) the company enjoys an exceptional market positioning. This new technology replaces the costly, time-consuming and laborious practices of bioassay-guided extract fractioning and dereplication.

This innovative concept has already resulted in the award of several substantial contracts to AnalytiCon from pharmaceutical corporations in Europe (Boehringer Ingelheim, Bayer), the US (amongst others Schering-Plough) and Japan. Currently, AnalytiCon has direct access to roughly a quarter of all known natural compounds worldwide (25,000 of 110,000), i.e. in their pure and structurally fully elucidated form. The Company is leading in the custom-design and development of combinational libraries based on rare natural compound structures (NatDiverse tailor-made). In structure elucidation of natural compounds it can offer the highest throughput available on the market (up to 50 structures per day). AnalytiCon currently employs 60 members of staff at the Biotech Campus Potsdam-Hermannswerder. Thanks to its exceptional position the company is able to offer its clients a complete Supply-Chain-Management from the initial biomaterial to the final lead compound.

Contact:
AnalytiCon Discovery GmbH
Dr. Matthias Heß
Hermannswerder Haus 17
D- 14473 Potsdam
Tel.: +49-(0)331-2300-318
Fax.: +49-(0)331-2300-333
eMail: m.hess@ac-discovery.com
Web: www.ac-discovery.com

Downloads: Available as RTF in „Presse Pool“: www.biocommunications.net